E-resources
-
Fong, Lawrence; Hotson, Andrew; Powderly, John D; Sznol, Mario; Heist, Rebecca S; Choueiri, Toni K; George, Saby; Hughes, Brett G M; Hellmann, Matthew D; Shepard, Dale R; Rini, Brian I; Kummar, Shivaani; Weise, Amy M; Riese, Matthew J; Markman, Ben; Emens, Leisha A; Mahadevan, Daruka; Luke, Jason J; Laport, Ginna; Brody, Joshua D; Hernandez-Aya, Leonel; Bonomi, Philip; Goldman, Jonathan W; Berim, Lyudmyla; Renouf, Daniel J; Goodwin, Rachel A; Munneke, Brian; Ho, Po Y; Hsieh, Jessica; McCaffery, Ian; Kwei, Long; Willingham, Stephen B; Miller, Richard A
Cancer discovery, 01/2020, Volume: 10, Issue: 1Journal Article
Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase I clinical trial with a small-molecule A2AR antagonist. We find that this molecule can safely block adenosine signaling . In a cohort of 68 patients with renal cell cancer (RCC), we also observe clinical responses alone and in combination with an anti-PD-L1 antibody, including subjects who had progressed on PD-1/PD-L1 inhibitors. Durable clinical benefit is associated with increased recruitment of CD8 T cells into the tumor. Treatment can also broaden the circulating T-cell repertoire. Clinical responses are associated with an adenosine-regulated gene-expression signature in pretreatment tumor biopsies. A2AR signaling, therefore, represents a targetable immune checkpoint distinct from PD-1/PD-L1 that restricts antitumor immunity. SIGNIFICANCE: This first-in-human study of an A2AR antagonist for cancer treatment establishes the safety and feasibility of targeting this pathway by demonstrating antitumor activity with single-agent and anti-PD-L1 combination therapy in patients with refractory RCC. Responding patients possess an adenosine-regulated gene-expression signature in pretreatment tumor biopsies. . .
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.